Because inhibiting Ero1α is likely to change the cytokine and chemokine profile of the tumor microenvironment, further studies are required to fully understand the effect of inhibiting Ero1α on tumor mediated immune suppression. The gene discussed is ERO1A; the disease is neoplasm.